Omomyc and kras inhibitors combination therapy for the treatment of cancer
AssigneesPeptomyc, S.L., Fundacio Privada Institut d'Investigacio Oncologica de Vall Hebron, Institució Catalana De Recerca I Estudis AvançAts
InventorsSílvia CASACUBERTA SERRA, Marie-Eve BEAULIEU, Laura SOUCEK, Íñigo GONZÁLEZ LARREATEGUI
Life of this patent
Estimating the term…
Abstract
The invention relates to a combination of a KRAS inhibitor with Omomyc, a functionally equivalent variant thereof, a conjugate comprising Omomyc or said functionally equivalent variant, a polynucleotide encoding said polypeptides, a vector comprising said polynucleotide and a cell capable of secreting the polypeptide or the conjugate. The invention also relates to pharmaceutical compositions containing the combination of the invention and to their medical uses, particularly their uses in the treatment of cancer.
Claims14
1-15. (canceled)
A combination comprising:
- i) a first component selected from the group consisting of:
- a) a polypeptide comprising the sequence SEQ ID NO:
- 1 or a functionally equivalent variant thereof;
- b) a conjugate comprising a polypeptide comprising the sequence SEQ ID NO:
- 1 or a functionally equivalent variant thereof and a chemical moiety that facilitates cellular uptake of the polypeptide or of the functionally equivalent variant thereof;
- c) a polynucleotide encoding the polypeptide of a) or the conjugate of b);
- d) a vector comprising the polynucleotide according to c);
- and
- e) a cell capable of secreting into the medium the polypeptide according to
- a) or the conjugate according to b);
- and
- ii) a second component that is a KRAS inhibitor, or
- a pharmaceutical composition comprising a pharmaceutically effective amount of said combination and a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.